691P DNA-based peripheral blood epigenetic immuno-profiling of recurrent/metastatic (R/M) squamous cell carcinoma of head and neck (SCCHN) treated with anti-programmed death (PD)-1 therapy

K Sehgal,M.K Lee,K.T Kelsey,Z Zhang,R Butler,S Donnelly,J.K Wiencke,D.C Koestler,B.C Christensen,L.A Salas,K Shirai,A Molinaro,R Haddad

doi:10.1016/j.annonc.2022.07.815

691P DNA-based peripheral blood epigenetic immuno-profiling of recurrent/metastatic (R/M) squamous cell carcinoma of head and neck (SCCHN) treated with anti-programmed death (PD)-1 therapy

K Sehgal, M.K Lee + Show 11 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.815

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2022
License type: publisher-specific-oa

Affiliation: Brown University, University of California, San Francisco

#Squamous Cell Carcinoma Of Head And Neck #Squamous Cell Carcinoma Of Head + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Clinically relevant biomarkers of response to anti-PD-1 therapy in R/M SCCHN are limited to PD-ligand-1 combined proportion score on tumor biopsies. This study aims to identify DNA based methylation biomarkers on easily accessible peripheral blood samples.

Full Text